Copeptin Stimulation by Combined Intravenous Arginine and Oral LevoDopa/Carbidopa in Healthy Short Children and Children with the Polyuria-Polydipsia Syndrome
Authors' conclusion
ALD-ST induced a robust peak copeptin in healthy short children and children with primary polydipsia. Nausea/vomiting, a side effect of ALD-ST, amplified the copeptin response. The ALD-ST may be a suitable initial screening test in children with PPS.
Study context
- Population
- Healthy short children and children with polyuria-polydipsia syndrome receiving IV arginine hydrochloride (500 mg/kg over 30 min) plus oral levodopa/carbidopa (175 mg L-Dopa/m² BSA); copeptin at 0, 60, 90, 120 min
- Participants
- 47 / 10 / 10
- Comparison
- Copeptin response to arginine + LevoDopa/Carbidopa stimulation test (ALD-ST) in controls, primary polydipsia and AVP deficiency
- Controlsn = 47reference
- Primary polydipsian = 10
- AVP deficiencyn = 10
- Outcome
- Serum copeptin (baseline and peak, 60–120 min)
Performance
As reported in the abstract
| Test or model | Value | Baseline median | Baseline |
|---|---|---|---|
| Controls | median 44.0 (IQR 21.4–181.0) pmol/L | 7.0 pmol/L (IQR 5.0-10.0) | |
| Primary polydipsia | 125.2 (IQR 87.6–174.0) pmol/L | 8.5 pmol/L (IQR 8.0-11.0) | |
| AVP deficiency | 4.6 (IQR 2.4–6.0) pmol/L | 2.5 pmol/L (IQR 2.0-3.1) |
Value
Controlsmedian 44.0 (IQR 21.4–181.0) pmol/L
Primary polydipsia125.2 (IQR 87.6–174.0) pmol/L
AVP deficiency4.6 (IQR 2.4–6.0) pmol/L
Baseline median
Controls7.0 pmol/L (IQR 5.0-10.0)
Primary polydipsia— not stated in the abstract
AVP deficiency— not stated in the abstract
Baseline
Controls— not stated in the abstract
Primary polydipsia8.5 pmol/L (IQR 8.0-11.0)
AVP deficiency2.5 pmol/L (IQR 2.0-3.1)
- Controls: copeptin rise from baseline to peak
- P < 0.001
- Peak copeptin ≥9.3 pmol/L predicting absence of complete or partial AVP deficiency: sensitivity
- 100%
- Peak copeptin ≥9.3 pmol/L: specificity
- 80%
Further findings
Peak copeptin by nausea or vomiting (controls) · higher with nausea or vomiting
P < 0.001
Safety
- Subjects with nausea or vomiting
- 57%
Original publication
Copeptin Stimulation by Combined Intravenous Arginine and Oral LevoDopa/Carbidopa in Healthy Short Children and Children with the Polyuria-Polydipsia Syndrome. Horm Res Paediatr. Published 3 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →